Latest Non-Redemption Agreements: Deep Medicine
Deep Medicine Acquisition Corporation (DMAQ) Adds Non-Redemption Agreement
As previously disclosed, Deep Medicine Acquisition Corp. (NASDAQ:DMAQ) and its sponsor, Bright Vision Sponsor LLC, have entered into certain non-redemption agreements with certain unaffiliated third parties in connection with the special meeting on July 13.
As of now, the company and the sponsor have entered into such non-redemption agreements with six unaffiliated third parties in total, with respect to a maximum aggregate of 514,773 shares of Class A common stock and the sponsor has agreed to transfer a maximum aggregate of 185,179 shares of Class A Common Stock pursuant to the Non-Redemption Agreements upon the consummation of a business combination.
READ
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....
1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...